New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
20:25 EDTPFE, PFE, PFE, PFE, AMGN, AMGN, AMGN, AMGN, PBYI, PBYI, PBYI, PBYI, LLY, LLY, LLY, LLY, MDVN, MDVN, MDVN, MDVN, CLDX, CLDX, CLDX, CLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
News For PFE;AMGN;PBYI;LLY;MDVN;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 23, 2015
10:02 EDTPBYI, MDVNOn the Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTMDVNMedivation recent weakness a buying opportunity, says UBS
Subscribe for More Information
January 22, 2015
16:16 EDTPBYIPuma Biotechnology initiated with an Outperform at RBC Capital
Subscribe for More Information
16:15 EDTMDVNMedivation initiated with a Sector Perform at RBC Capital
Subscribe for More Information
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
09:16 EDTMDVNOn The Fly: Pre-market Movers
Subscribe for More Information
07:36 EDTPBYIPuma Biotechnology a 'unique takeout candidate,' says Citigroup
Subscribe for More Information
07:13 EDTMDVNMedivation up 1.2% after Phase 2 TERRAIN trial achieved primary endpoint
07:12 EDTMDVNMedivation phase 2 TERRAIN trial achieved primary endpoint
Subscribe for More Information
January 21, 2015
19:13 EDTPBYIPuma Biotechnology 1M share Secondary priced at $190.00
Subscribe for More Information
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTLLY, AMGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:25 EDTPBYIPuma Biotechnology files to sell 1M shares of common stock
Subscribe for More Information
16:07 EDTPBYIPuma Biotechnology files automatic mixed securities shelf
Subscribe for More Information
January 15, 2015
16:04 EDTAMGNAmgen announces new data from Phase 2 PEAK, Phase 3 PRIME studies
Amgen announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix in combination with Folfox, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS metastatic colorectal cancer. In an exploratory analysis from the PEAK study, treatment with Vectibix compared to Avastin resulted in a "significantly higher proportion" of patients with earlier tumor shrinkage at week eight, 64% vs. 45%, respectively, and among responding patients, a longer duration of response, 11.4 vs. 8.5 months, respectively, and greater depth of response . Overall response rates appeared to be similar between Vectibix and Avastin. This is consistent with observed overall survival and progression-free survival (PFS) rates, and with data previously reported, Amgen said. It added, "While the primary analysis from PEAK showed similar ORR between the Vectibix- and bevacizumab-based regimens, this exploratory analysis demonstrates that Vectibix produces early, sustained anti-tumor activity, which may in part explain the OS and PFS benefits seen with Vectibix versus bevacizumab in this trial."
11:20 EDTLLY, PFE, MDVNGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:59 EDTPFE, AMGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use